Fig. 1: Changes in compound motor action potential (CMAP) amplitude (amp) of the ulnar nerve against age in 12 infants with spinal muscular atrophy (SMA) identified through a newborn screening program. | Genetics in Medicine

Fig. 1: Changes in compound motor action potential (CMAP) amplitude (amp) of the ulnar nerve against age in 12 infants with spinal muscular atrophy (SMA) identified through a newborn screening program.

From: CMAP changes upon symptom onset and during treatment in spinal muscular atrophy patients: lessons learned from newborn screening

Fig. 1

The infants are grouped into those with two (red), three (blue), and four (green) copies of SMN2. Changes in the pretreatment periods are connected by dashed lines, and changes after nusinersen treatment are connected by solid lines. The upper right insert is an enlargement of the infants with two copies of SMN2 at age 0–6 months, to better show the rapid decline in CMAP amplitude in the first month of age.

Back to article page